News | October 30, 2023
Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19
The companies plan to start a pivotal Phase 3 trial in the coming months
The companies plan to start a pivotal Phase 3 trial in the coming months
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Pfizer is likely to show GSK significant competition
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
The company has reported total income of Rs. 604.02 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
